Contrasting Cerus (NASDAQ:CERS) & Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Omeros and Cerus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1	1	2	2	2.83
Cerus	1	1	2	0	2.25

Omeros presently has a consensus price target of $38.00, indicating a potential upside of 273.10%. Cerus has a consensus price target of $4.00, indicating a potential upside of 20.30%. Given Omeros’ stronger consensus rating and higher possible upside, equities analysts plainly believe Omeros is more favorable than Cerus.

Profitability

This table compares Omeros and Cerus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Cerus	-4.41%	-15.18%	-4.38%

Earnings and Valuation

This table compares Omeros and Cerus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35 million	$0.70	14.55
Cerus	$206.13 million	3.23	-$15.63 million	($0.05)	-66.50

Omeros has higher earnings, but lower revenue than Cerus. Cerus is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Omeros has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500. Comparatively, Cerus has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Insider and Institutional Ownership

48.8% of Omeros shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 3.4% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Omeros beats Cerus on 10 of the 13 factors compared between the two stocks.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.